Literature DB >> 31251797

Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis.

Sourya Shrestha1, Sarah Cherng1, Andrew N Hill2, Sue Reynolds2, Jennifer Flood3, Pennan M Barry3, Adam Readhead3, Margaret Oxtoby4, Michael Lauzardo5, Tom Privett6, Suzanne M Marks2, David W Dowdy1.   

Abstract

The incidence of tuberculosis (TB) in the United States has stabilized, and additional interventions are needed to make progress toward TB elimination. However, the impact of such interventions depends on local demography and the heterogeneity of populations at risk. Using state-level individual-based TB transmission models calibrated to California, Florida, New York, and Texas, we modeled 2 TB interventions: 1) increased targeted testing and treatment (TTT) of high-risk populations, including people who are non-US-born, diabetic, human immunodeficiency virus (HIV)-positive, homeless, or incarcerated; and 2) enhanced contact investigation (ECI) for contacts of TB patients, including higher completion of preventive therapy. For each intervention, we projected reductions in active TB incidence over 10 years (2016-2026) and numbers needed to screen and treat in order to avert 1 case. We estimated that TTT delivered to half of the non-US-born adult population could lower TB incidence by 19.8%-26.7% over a 10-year period. TTT delivered to smaller populations with higher TB risk (e.g., HIV-positive persons, homeless persons) and ECI were generally more efficient but had less overall impact on incidence. TTT targeted to smaller, highest-risk populations and ECI can be highly efficient; however, major reductions in incidence will only be achieved by also targeting larger, moderate-risk populations. Ultimately, to eliminate TB in the United States, a combination of these approaches will be necessary. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2019.

Entities:  

Keywords:  mathematical modeling; preventative therapy; tuberculosis; tuberculosis prevention

Mesh:

Year:  2019        PMID: 31251797      PMCID: PMC6736179          DOI: 10.1093/aje/kwz147

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  24 in total

1.  A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States.

Authors:  Anne Marie France; Juliana Grant; J Steve Kammerer; Thomas R Navin
Journal:  Am J Epidemiol       Date:  2015-10-13       Impact factor: 4.897

2.  Revisiting rates of reactivation tuberculosis: a population-based approach.

Authors:  C Robert Horsburgh; Max O'Donnell; Sandra Chamblee; Janet L Moreland; Johnny Johnson; Bryan J Marsh; Masahiro Narita; Linda Scoles Johnson; C Fordham von Reyn
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

3.  Tuberculosis Contact Investigations--United States, 2003-2012.

Authors:  Kai H Young; Melissa Ehman; Randall Reves; Brandy L Peterson Maddox; Awal Khan; Terence L Chorba; John Jereb
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

4.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

5.  The Prevalence of Latent Tuberculosis Infection in the United States.

Authors:  James D Mancuso; Jeffrey M Diffenderfer; Bijan J Ghassemieh; David J Horne; Tzu-Cheg Kao
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

6.  The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

Authors:  Timothy R Sterling; James Bethel; Stefan Goldberg; Paul Weinfurter; Lourdes Yun; C Robert Horsburgh
Journal:  Am J Respir Crit Care Med       Date:  2006-01-19       Impact factor: 21.405

7.  Modelling tuberculosis trends in the USA.

Authors:  A N Hill; J E Becerra; K G Castro
Journal:  Epidemiol Infect       Date:  2012-01-11       Impact factor: 2.451

8.  Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup.

Authors:  Kimberly M Shea; J Steve Kammerer; Carla A Winston; Thomas R Navin; C Robert Horsburgh
Journal:  Am J Epidemiol       Date:  2013-10-18       Impact factor: 4.897

9.  Increased risk of tuberculosis among foreign-born persons with diabetes in California, 2010-2012.

Authors:  Sarah Ellen Demlow; Peter Oh; Pennan M Barry
Journal:  BMC Public Health       Date:  2015-03-18       Impact factor: 3.295

10.  Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Roque Miramontes; Andrew N Hill; Rachel S Yelk Woodruff; Lauren A Lambert; Thomas R Navin; Kenneth G Castro; Philip A LoBue
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more
  7 in total

1.  Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.

Authors:  Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

2.  The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.

Authors:  Nicolas A Menzies; Sourya Shrestha; Andrea Parriott; Suzanne M Marks; Andrew N Hill; David W Dowdy; Priya B Shete; Ted Cohen; Joshua A Salomon
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822

3.  Health insurance, healthcare utilization and language use among populations who experience risk for tuberculosis, California 2014-2017.

Authors:  Adam Readhead; Jennifer Flood; Pennan Barry
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

4.  Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.

Authors:  Sourya Shrestha; Andrea Parriott; Nicolas A Menzies; Priya B Shete; Andrew N Hill; Suzanne M Marks; David W Dowdy
Journal:  Ann Am Thorac Soc       Date:  2020-12

5.  Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas.

Authors:  Youngji Jo; Sourya Shrestha; Isabella Gomes; Suzanne Marks; Andrew Hill; Garrett Asay; David Dowdy
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

6.  Bacteria Associated with Healthcare-Associated Infections on Environmental Samples Obtained from Two Fire Departments.

Authors:  Kelli L Barr; Rodney X Sturdivant; Denise N Williams; Debra Harris
Journal:  Int J Environ Res Public Health       Date:  2021-11-12       Impact factor: 3.390

7.  Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.

Authors:  Nicolas A Menzies; Andrea Parriott; Sourya Shrestha; David W Dowdy; Ted Cohen; Joshua A Salomon; Suzanne M Marks; Andrew N Hill; Carla A Winston; Garrett R Asay; Pennan Barry; Adam Readhead; Jennifer Flood; James G Kahn; Priya B Shete
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.